A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults

NCT04822025 | Completed Phase 2 DMC

• 1 other identifier: CT-COV-23
• Study Type: interventional
• Target: 420
• Locations: 1 country
• Sites: 4

Brief Summary

The purpose of this study is to assess the safety and immunogenicity of MVC-COV1901 vaccine in two different dose forms in participants who are generally healthy or with stable pre-existing health conditions.

Conditions

Covid19 Vaccine

Keywords

Covid19 vaccine

Outcome Measures

Primary Outcomes (2)

• Incidence of Adverse Events(AEs) [Safety and Tolerability]

  To evaluate the incidence of Adverse Events(AEs) of MVC-COV1901 from Visit 2 (Day 1) to Visit 6 (28 days after the second dose of study intervention) in terms of the number and percentage of participants with the occurrence of: Solicited local AEs (up to 7 days after each dose of study intervention) Solicited systemic AEs (up to 7 days after each dose of study intervention) Unsolicited AEs (up to 28 days after each dose of study intervention) AE of Special Interest (AESI) Vaccine-Associated Enhanced Disease(VAED) Serious adverse events (SAEs)

  Day 1 to 28 days after the second vaccination

• Immunogenicity of MVC-COV1901

  To evaluate the immunogenicity of High-dose MVC-COV1901, as compared to Mid-dose MVC-COV1901, in terms of neutralizing antibody titers.

  Day 1 to 28 days after the second vaccination

Secondary Outcomes (2)

• Incidence of Adverse Events(AEs) [Safety and Tolerability]

  Day 1 to 180 days after the second vaccination

• Immunogenicity of MVC-COV1901

  Day 1 to 180 days after the second vaccination

Study Arms (2)

High Dose

EXPERIMENTAL

High-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL

Biological: MVC-COV1901 (High-Dose)

Mid Dose

EXPERIMENTAL

Mid-Dose S-2P protein with CpG and Aluminum Hydroxide/0.5mL

Biological: MVC-COV1901(Mid-Dose)

Interventions

MVC-COV1901 (High-Dose) BIOLOGICAL

Approximately 300 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region

High Dose

MVC-COV1901(Mid-Dose) BIOLOGICAL

Approximately 100 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region

Mid Dose

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Older Adult (65+)

You may qualify if:

• Male or female participant ≥ 65 years of age at randomization.
• Healthy adults or adults with pre-existing medical conditions who are in stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease 3 months before enrollment and expected to remain stable for the duration of the study.
• Participant is willing and able to comply with all required study visits and follow-up required by this protocol.
• Participant has not travelled overseas within 14 days of screening and will not have any oversea traveling throughout the study period.
• Participant is able to understand and comply with study requirements/procedures (if applicable, with assistance by caregiver, surrogate, or legally authorized representative) based on the assessment of the investigator and must provide written informed consent.

You may not qualify if:

• Employees at the investigator's site, of the Sponsor or the contract research organization (CRO) who are directly involved in the conduct of the study.
• Currently receiving or received any investigational intervention within 30 days prior to the first dose of study intervention.
• Administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to the first dose of study intervention.
• Administered any blood product or intravenous (IV) immunoglobulin administration within 12 weeks prior to the first dose of study intervention.
• Participant previously received any coronavirus vaccine.
• Currently receiving or anticipate to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or \< 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the first dose of study intervention.
• Currently receiving or anticipate to receive treatment with tumor necrosis factor (TNF)-α inhibitors, e.g. infliximab, adalimumab, etanercept within 12 weeks prior to the first dose of study intervention.
• Major surgery or any radiation therapy within 12 weeks prior to the first dose of study intervention.
• Immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia.
• A history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator).
• Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy.
• Participant with known human immunodeficiency virus (HIV) infection or who is HIV antibody positive, with CD4 count \< 350 cells/mm3 or a detectable HIV viral load within the past year (low level variations from 50-500 viral copies/mL or equivalent which do not lead to changes in antiretroviral therapy \[ART\] are permitted).
• Participant who, in the investigator's judgement, is not in stable condition and by participating in the study could adversely affect the safety of the participant, interfere with adherence to study requirements or evaluation of any study endpoint. This may include aparticipant with ongoing acute diseases, severe infections, autoimmune disease, laboratory abnormality or serious medical conditions in the following systems: cardiovascular, pulmonary, hepatic, neurologic, metabolic, renal, or psychiatric.
• Participant with previous known SARS-CoV-1 or 2 infection or potential exposure to SARS-CoV-1 or 2 viruses (EXCEPT for those who have been tested negative or completed the self-managements/ home quarantines/ home isolations)
• Participant with a history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the MVC-COV1901.

Sponsors & Collaborators

• Medigen Vaccine Biologics Corp.: lead

Study Sites (4)

Hualien Tzu Chi Hospital

Hualien City, Taiwan

Location

Shuang H Hospital

New Taipei City, Taiwan

Location

National Taiwan University Hospital

Taipei, Taiwan

Location

Chang Gung Medical Hospital Linkou

Taoyuan District, Taiwan

Location

Related Publications (1)

• Waits A, Chen JY, Cheng WH, Yeh JI, Hsieh SM, Chen C, Janssen R, Lien CE, Lin TY. Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial. Int J Infect Dis. 2022 Nov;124:21-26. doi: 10.1016/j.ijid.2022.08.021. Epub 2022 Aug 29.

  PMID: 36049700 DERIVED

MeSH Terms

Interventions

MVC-COV1901 vaccine

Study Officials

• Szu-Min Hsieh, MD

  National Taiwan University Hospital

  PRINCIPAL INVESTIGATOR

• Tzou-Yien Lin, MD

  Chang Gang Memorial Hospital, LinKou

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 25, 2021
• First Posted: March 30, 2021
• Study Start: May 20, 2021
• Primary Completion: August 25, 2021
• Study Completion: January 28, 2022
• Last Updated: June 28, 2022

Record last verified: 2021-06

Data Sharing

• IPD Sharing: Will not share

Locations

TW (4)